Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Pandion Therapeutics, Inc. (PAND)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-20Sep-30-20Jun-30-20Mar-31-20Dec-31-19Sep-30-19Jun-30-19Mar-31-19
   10-K10-Q10-QS-1/A10-K10-Q10-QS-1/A
Revenue  2.22.62.01.01.0  8.4
            Revenue growth  126.6%  -88.5%    
Operating expenses          
Research and development  8.89.38.9 3.84.44.9 
General and administrative  4.64.32.35.01.91.50.82.7
    Total operating expenses  13.413.611.223.25.65.95.811.0
    Loss from operations  -11.2-11.0-9.2-22.2-4.7-5.9-5.8-11.0
            Operating margin  -512.5%-417.6%-470.7%-2297.7%   -131.7%
Interest income  0.00.00.00.30.10.10.10.2
Interest expense  0.0-0.30.00.0   0.0
    Net loss  -11.2-11.2-9.2-21.9-4.5-5.8-5.7-10.9
Change in redemption value of redeemable convertible preferred shares   -0.7-2.7 -1.0-1.0-1.0 
    Net loss attributable to common shares – basic and diluted  -11.2-11.9-11.90.0-5.6-6.9-6.70.0
   
Net loss per common share, basic and diluted  $0.54($0.51)($10.15)($25.00)($5.09)($6.72)($6.30)($17.00)
   
Weighted-average number of shares used in computing net loss per common share, basic and diluted  13.623.31.20.01.01.01.10.0

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy